Johnson & Johnson to Acquire Intra-Cellular Therapies

Intra-Cellular Therapies ( (ITCI) ) just unveiled an update.

Johnson & Johnson has entered into an agreement to acquire Intra-Cellular Therapies for approximately $14.6 billion, enhancing its neuroscience portfolio with Intra-Cellular’s CAPLYTA® and promising pipeline. The acquisition positions Johnson & Johnson strategically for growth in the neuropsychiatric and neurodegenerative disorder markets, as CAPLYTA® has the potential to become a standard treatment for major depressive disorder if approved by the FDA.

More about Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system disorders. Its primary product, CAPLYTA® (lumateperone), is approved for treating schizophrenia and depressive episodes associated with bipolar I or II disorder.

YTD Price Performance: 12.62%

Average Trading Volume: 622,352

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $10.06B

For an in-depth examination of ITCI stock, go to TipRanks’ Stock Analysis page.